The Indian pharmaceuticals group refuted a media report that the Department of Drug Administration, Nepal has suspended sales and distribution of Biotax 1gm due to "serious health risks" stating these were "misleading and erroneous" as it complies with all quality parameters as per approved specification. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
